Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipranavir/Ritonavir Dosing in Treatment-Naïve HIV-1
NCT00530920Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2007
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of tipranavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Boehringer Ingelheim. Started Oct 2007; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00530920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00530920.